Picture of Teradyne logo

TER — Teradyne News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyAdventurousLarge CapHigh Flyer

Teradyne beats Q3 revenue, adjusted EPS estimates on AI-related test demand

Overview

Semiconductor testing tools maker Teradyne Q3 revenue rises 4% yr/yr to $769 mln, beating analyst expectations

Adjusted EPS for Q3 beats consensus, driven by Semiconductor Test performance

Company expects Q4 revenue to rise 25% sequentially, driven by AI demand

Outlook

Teradyne expects Q4 2025 revenue between $920 mln and $1,000 mln

Company forecasts Q4 2025 GAAP EPS of $1.12 to $1.39

Teradyne anticipates Q4 2025 non-GAAP EPS of $1.20 to $1.46

Result Drivers

SEMICONDUCTOR TEST - Strong performance in Semiconductor Test, especially in System-on-a-Chip solutions for AI applications, drove Q3 results

AI DEMAND - Robust AI-related demand in compute, networking, and memory segments expected to continue into Q4

Key Details

MetricBeat/MissActualConsensus Estimate
Q3 RevenueBeat$769 mln$743.77 mln (14 Analysts)
Q3 Adjusted EPSBeat$0.85$0.78 (15 Analysts)
Q3 EPS$0.75
Q3 Adjusted Net IncomeBeat$135.90 mln$124.17 mln (12 Analysts)
Q3 Net Income$119.60 mln
Analyst Coverage The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 9 "strong buy" or "buy", 6 "hold" and 3 "sell" or "strong sell" The average consensus recommendation for the semiconductor equipment & testing peer group is "buy." Wall Street's median 12-month price target for Teradyne Inc is $135.00, about 9.3% below its October 27 closing price of $147.50 The stock recently traded at 34 times the next 12-month earnings vs. a P/E of 23 three months ago Press Release: ID:nBw7VMCXna For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Teradyne

See all news